Mathilde Boussac1, Christophe Arbus2, Julia Dupouy3, Estelle Harroch3, Vanessa Rousseau3, Fabienne Ory-Magne1,2,3, Olivier Rascol3, Caroline Moreau4, David Maltête5, Tiphaine Rouaud6, Mylène Meyer7, Jean Francois Houvenaghel8, Claire Marsé9, Christine Tranchant10, Elodie Hainque11, Béchir Jarraya12, Solène Ansquer13, Marie Bonnet14, Lhaouas Belamri15, Mélissa Tir16, Ana-Raquel Marques17, Teodor Danaila18, Alexandre Eusebio19, David Devos4, Christine Brefel-Courbon1,2,3. 1. ToNIC, Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France. 2. Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France. 3. Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France. 4. CHU of Lille, Univ. Lille, Inserm UMRS_1171, Licend, Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's Disease, Lille, France. 5. Department of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France. 6. Clinique Neurologique, Hôpital Guillaume et René Laennec, Boulevard Jacques Monod, Nantes Cedex. 7. Neurology Department, Nancy University Hospital, Nancy, France. 8. Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes Cedex, France. 9. CHU Nice, Centre Expert Parkinson, Service de Neurologie, Nice, France. 10. Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France. 11. Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, Paris, France. 12. Pôle Neurosciences, Foch Hospital, Suresnes, France; Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, Paris, France. 13. Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, Poitiers, France. 14. CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France. 15. Fondation Ophtalmologique A de Rothschild, Unité James Parkinson, Paris, France. 16. Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's Disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), Amiens, France. 17. Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France. 18. Centre Expert Parkinson, Hôpital Neurologique "Pierre Wertheimer", Hospices Civils de Lyon, Bron, France. 19. Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, Marseille, France.
Abstract
BACKGROUND: Parkinson's disease (PD) negatively affects patients' Quality of Life (QoL) which depends on both objective criteria such as physical health and subjective ones such as worries and norms according to personal believes. Therefore, QoL could be also associated to personality dimensions in chronic neurological diseases such as PD. OBJECTIVE: Our objective was thus to study the potential association between personality dimensions and QoL in PD patients with motor fluctuations before Deep Brain Stimulation of the Sub-Thalamic Nucleus (DBS-STN). METHODS: Data were obtained from the French multicentric cohort study Predi-Stim. All PD patients awaiting DBS-STN and responding to the inclusion criteria at the time of the study were included. All participants answered the "Temperament and Character Inventory" (TCI) and the PDQ-39 before surgery. Analyses were made using adjusted univariate generalized linear regression models to evaluate a potential association between TCI dimensions and PDQ-39 scores. RESULTS: Three hundred thirty-three consecutive patients were included. The temperament Harm Avoidance was negatively associated with QoL (p = 1e-4, R2= 0.33), whereas the character Self-Directedness was positively associated with mental component of QoL (p = 2e-4, R2= 0.33) in PD patients with motor fluctuations awaiting DBS-STN. CONCLUSIONS: PD patients with motor fluctuations, with lower Harm Avoidance and higher Self-Directedness scores have the best QoL mainly at an emotional and social level. Therapeutic education of these PD patients focusing on their personal resources may thus be important to improve their well-being.
BACKGROUND:Parkinson's disease (PD) negatively affects patients' Quality of Life (QoL) which depends on both objective criteria such as physical health and subjective ones such as worries and norms according to personal believes. Therefore, QoL could be also associated to personality dimensions in chronic neurological diseases such as PD. OBJECTIVE: Our objective was thus to study the potential association between personality dimensions and QoL in PDpatients with motor fluctuations before Deep Brain Stimulation of the Sub-Thalamic Nucleus (DBS-STN). METHODS: Data were obtained from the French multicentric cohort study Predi-Stim. All PDpatients awaiting DBS-STN and responding to the inclusion criteria at the time of the study were included. All participants answered the "Temperament and Character Inventory" (TCI) and the PDQ-39 before surgery. Analyses were made using adjusted univariate generalized linear regression models to evaluate a potential association between TCI dimensions and PDQ-39 scores. RESULTS: Three hundred thirty-three consecutive patients were included. The temperament Harm Avoidance was negatively associated with QoL (p = 1e-4, R2= 0.33), whereas the character Self-Directedness was positively associated with mental component of QoL (p = 2e-4, R2= 0.33) in PDpatients with motor fluctuations awaiting DBS-STN. CONCLUSIONS:PDpatients with motor fluctuations, with lower Harm Avoidance and higher Self-Directedness scores have the best QoL mainly at an emotional and social level. Therapeutic education of these PDpatients focusing on their personal resources may thus be important to improve their well-being.
Entities:
Keywords:
Character; Parkinson’s disease; personality; quality of life; temperament
Authors: Alicja Popiołek; Bartosz Brzoszczyk; Piotr Jarzemski; Małgorzata Piskunowicz; Marcin Jarzemski; Alina Borkowska; Maciej Bieliński Journal: Cancer Manag Res Date: 2022-05-20 Impact factor: 3.602